نتایج جستجو برای: daclatasvir
تعداد نتایج: 714 فیلتر نتایج به سال:
After entering hepatocytes, the viral genome of the hepatitis C virus (HCV) is translated into a single polypeptide. This polypeptide is subsequently cleaved into viral proteins, including non-structural (NS) proteins NS3, NS4A, NS5B and NS5B RNA dependent RNA polymerase (Figure 1) [3, 4]. These viral proteins are essential for viral replication and assembly making them significant targets for ...
Objective: compare the efficacy of daily Sofosbuvir plus Declatasvir with alternate day and in HCV patients on hemodialysis. Study design: Randomized clinical trial Place duration: department general medicine Nishtar hospital, Multan from March 2020 to 2021 one year duration. Methodology: A total 260 were enrolled study divided into two groups (1 2) by convenient sampling technique. Non probabi...
Small push-pull molecules attract much attention as prospective donor materials for organic solar cells (OSCs). By chemical engineering, it is possible to combine a number of attractive properties such as broad absorption, efficient charge separation, and vacuum and solution processabilities in a single molecule. Here we report the synthesis and early time photophysics of such a molecule, TPA-2...
There is currently minimal clinical experience regarding retreatment options for patients failing direct-acting antiviral combination regimens. Here, we report the outcomes of a HCV genotype 1b-infected patient with virologic failure following treatment with daclatasvir and asunaprevir, who was successfully retreated with sofosbuvir plus simeprevir.
BACKGROUND Several combinations of 2 or 3 direct-acting antivirals (DAAs) can cure hepatitis C virus (HCV) in the majority of treatment-naive patients. DAAs for HCV infection have similar mechanisms of action and chemical structures to antiretrovirals for human immunodeficiency virus (HIV) infection. Generic antiretrovirals are currently manufactured at very low prices, to treat 10 million peop...
A phase 2 study of an interferon-free combination daclatasvir (BMS-790052, Bristol-Meyers Squibb) plus GS-7977 (formerly PSI-7977, Pharmasset/Gilead), with or without ribavirin, showed that this regimen was well tolerated and that treatmentnaive patients with hepatitis C virus (HCV) genotype 1, 2, and 3 infection achieved high rates of early sustained virological responses (SVRs). Investigators...
BACKGROUND All-oral combination therapy is desirable for patients with chronic hepatitis C virus (HCV) infection. We evaluated daclatasvir (an HCV NS5A replication complex inhibitor) plus sofosbuvir (a nucleotide analogue HCV NS5B polymerase inhibitor) in patients infected with HCV genotype 1, 2, or 3. METHODS In this open-label study, we initially randomly assigned 44 previously untreated pa...
using daclatasvir and sofosbuvir in treatment-naive, non-cirrhotic HCV genotype 3 Pakistani population. Methodology: From January 2017 to February 2019, patients who met the inclusion criteria were included this open-label, non-randomized, uncontrolled observational trial at HBS General Hospital Islamabad. A 12-week course of oral therapy was administered each participant. Each patient got 400m...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید